A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)
I1F-MC-RHBF - ClinicalTrials.gov - NCT02584855
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Psoriatic ArthritisWhat the trial is testing?
IxekizumabCould I receive a Placebo?
YesEnrollment Goal
394Trial Dates
Sep 14, 2015 - Oct 30, 2018How long will I be in the trial?
Your participation could last up to 2.5 years and include 32 visits to the study center.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo